**Supplement 6:** Summary of study results: prevalence by sex in children

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Author, year, reference;  and age if applicable | female | | Male | | female | | male | | female | | male | | female | | male | |
| Point prevalence  prevalence  (%, year if applicable) | 95% CI | Point prevalence  (%) | 95% CI | Itchy rash during the last 12 months  (place if applicable, %, year if applicable) | 95% CI | Itchy rash during the last 12 months  (place if applicable, %, year if applicable) | 95% CI | Eczema ever doctor diagnosed  (place if applicable, %, year if applicable) | 95% CI | Eczema ever doctor diagnosed  (place if applicable, %, year if applicable) | 95% CI | Eczema ever for more than 6 months  (place if applicable, %, year if applicable) | 95% CI | Eczema ever for more than 6 months  (place if applicable, %, year if applicable) | 95% CI |
| Agarwal P et al. 2014 (325) | 38.0 of all with AD# |  | 62.0 of all with AD# |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Akcay et al. 2014 (39) | 8.5 |  | 7.2 |  | 12.2 |  | 12.1 |  | 13.2 |  | 12.5 |  |  |  |  |  |
| Alqahtani JM et al. 2016 (198) | 4.7 |  | 5.2 |  | 9.1 |  | 12.0 |  | 12.1 |  | 12.9 |  |  |  |  |  |
| Al-Riyami BM et al. 2003 (199) 6-7 y | 10.2 |  | 10.3 |  |  |  | 5.2 |  | 6.2 |  |  |  | 8.0 |  | 6.8 |  |
| Al-Riyami BM et al. 2003 (199) 13-14 y | 11.7 |  | 13.4 |  |  |  | 5.2 |  | 5.2 |  |  |  | 14.6 |  | 14.2 |  |
| Al-Sahab B et al. 2008 (201) |  |  |  |  |  |  |  |  | 14.0 |  | 11.4 |  |  |  |  |  |
| Al-Sindi H et al. 2014 (327) |  |  |  |  | 8.5 |  | 12.0 |  |  |  |  |  |  |  |  |  |
| Amarasekera ND et al. 2010 (202) | 5.1 | 2.2 - 8.0 | 5.0 | 2.3 - 7.6 |  |  |  |  |  |  |  |  |  |  |  |  |
| Arrais M et al. 2017 (204) |  |  |  |  | 22.5 |  | 17.6 |  |  |  |  |  | 28.2 |  | 20.3 |  |
| Arrais M et al. 2019 (205) |  |  |  |  | No difference between sex# |  | No difference between sex# |  |  |  |  |  |  |  |  |  |
| Burgess JA et al. 2008 (85) |  |  |  |  |  |  |  |  | Flexural eczema, significantly more common in boys.# |  |  |  |  |  |  |  |
| Chen GY et al. 2008 (226) | More boys affected than girls ratio: 1.49:1# |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Christiansen et al. 2016 (230) |  |  |  |  |  |  |  |  |  |  |  |  | 7.0 |  | 5.0 |  |
| Civelek et al. 2011 (35) | 58.7% of all with current eczema# |  | 51.3% of all with current eczema# |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Dell et al. 2010 (235) |  |  |  |  |  |  |  |  | 20.9 |  | 21.9 |  | 23.9 |  | 24.7 |  |
| Dogra et al. 2003 (236) |  |  |  |  |  |  |  |  |  |  |  |  | 4.8 |  | 5.5 |  |
| Dogruel et al. 2016 (79) | 24.0 |  | 35.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Dotterud et al. 1994 (242) |  |  |  |  |  |  |  |  |  |  |  |  | 27.6 |  | 18.7 |  |
| Droma et al. 2007 (243) |  |  |  |  | 2.0 |  | 8.0 |  | 20.0 |  | 25.0 |  |  |  |  |  |
| Farajzadeh et al. 2014 (382) |  |  |  |  |  |  |  |  |  |  |  |  | 38.0 |  | 41.0 |  |
| Frankel HC et al. 2010 (387) |  |  |  |  |  |  |  |  |  |  |  |  | 53% of all with AD# |  | 47% of all with AD# |  |
| Fukiwake N et al. 2011 (388) |  |  |  |  | no significant difference between boys and girls | | | |  |  |  |  |  |  |  |  |
| Habbick BF 1999 (391)  6-7y |  |  |  |  |  |  |  |  |  |  |  |  | 20.0-22.2 |  | 21.3-22.1 |  |
| 215 Habbick BF 1999 (391)  13-14y |  |  |  |  |  |  |  |  |  |  |  |  | 18.3-20.7 |  | 10.5-13.6 |  |
| Kabir et al. 2005 (260) | 6.2 |  | 6.8 |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Kim CW et al. (78) | 11.1 |  | 8.1 |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Kurt E et al. 2009 (354) | 13.1(rural)  7.3(urban) | 12.4-13.8(rural)  6.9-7.7%)(urban) | 10.8(rural)  6.6%(urban) | 10.2-11.4(rural)  6.2-7.0 (urban) |  |  |  |  |  |  |  |  |  |  |  |  |
| Lima RG et al. 2007 (280) |  |  |  |  | 13.5 |  | 12.2 |  | Eczema ever 6.1 |  | Eczema ever 12.8 |  | Itchy rash ever  19.1 |  | Itchy rash ever  17.6 |  |
| López-Perez G et al. 2001 (283) | 56.7% of all with AD# |  | 43.3% of all with AD# |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Maziak et al. 2003 (72)  6-7y |  |  |  |  | 9.4, 1994/5-2002  11.1, 1999-2000 |  | 5.0;1994/5-2002  4.5;1999-2000 |  | 14.6;1994/5-2002  16.9;1999-2000 |  | 14.3;1994/5-2002  13.6;1999-2000 |  |  |  |  |  |
| Maziak et al. 2003 (72)  13-14y |  |  |  |  | 6.7%1994/5-2002  9.8;1999-2000 |  | 7.3; 1994/5-2002  6.6;1999-2000 |  | 12.3;1994/5-2002  17.4;1999-2000 |  | 8.2;1994/5-2002  10.9;1999-2000 |  |  |  |  |  |
| Okada Y et al. 2016 (295) |  |  | 67 |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Peroni DG et al. 2008 (358) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Porto Neto AC et al. 2006 (296) |  |  |  |  | 10.5 |  | 6.7 |  | 15.3 |  | 11.4 |  | 15.7 |  | 11.4 |  |
| Shamssain et al. 2007 (73)  6-7y |  |  |  |  | 12-month prevalence of current rash  16.9, 1995-96  25.0, 2001-02 |  | 12-month prevalence of current rash  15.8, 1995-96  24.2, 2001-02 |  | 27.0, 1995-96  35.5, 2001-02 |  | 27.8, 1995-96  37.0, 2001-02 |  | Lifetime prevalence of rash  18.7, 1995-96  22.5, 2001-02 |  | Lifetime prevalence of rash  17.8, 1995-96  21.0, 2001-02 |  |
| Shamssain et al. 2007 (73)  13-14y |  |  |  |  | 20.5, 1995-96  20.9, 2001-02 |  | 11.3, 1995-96  16.8, 2001-02 |  |  |  |  |  | 22.8, 1995-96  17.5, 2001-02 |  | 13.9, 1995-96  15.3, 2001-02 |  |
| Stensen L et al. 2008 (311) | 18.1; 1986  28.7, 2001 |  | 16.4, 1986  25.7, 2001 |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Vellinga et al. 2005 (119)  6-7y |  |  |  |  | 11.9, 1996  14.7, 2002 |  | 8.5, 1996  11.4, 2002 |  | 15.7, 1996  19.8, 2002 |  | 12.9, 1996  18.4, 2002 |  |  |  |  |  |
| Vellinga et al. 2005 (119)  13-14y |  |  |  |  | 13.3, 1996  13.6, 2002 |  | 9.7, 1996  8.5, 2002 |  | 19.0, 1996  20.3, 2002 |  | 15.7, 1996  13.3, 2002 |  |  |  |  |  |
| Wu WF et al. 2011 (371) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Yang, Y. C. et al. 2007 (21) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Yuksel H et al. 2008 (45) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Zamanfar D et al. 2001 (80) |  |  |  |  | 9.6 |  | 17.1 |  |  |  |  |  |  |  |  |  |
| Zar HJ et al. 2002 (56) |  |  |  |  | 11.1 , 1995  18.8 , 2002 |  | 7.6 , 1995  13.5 , 2002 |  |  |  |  |  |  |  |  |  |
| Zhao T et al. 2000 (27) |  |  |  |  | 2.9  (Bejing)  2.0  (Urumqi) |  | 2.7  (Bejing)  2.0  (Urumqi) |  | 35.1  (Bejing)  24.7  (Urumqi) |  | 37.3  (Bejing)  26.0% (Urumqi) |  | 3.7  (Bejing)  3.1  (Urumqi) |  | 3.8  (Bejing)  3.8  (Urumqi) |  |

**Supplement 7:** Summary of study results prevalence by sex in children and adults

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Author, year, reference;  and age if applicable | female | | male | | female | | male | | female | | male | | female | | male | |
| Point prevalence  prevalence  (%, year if applicable&) | 95% CI | Point prevalence  (%) | 95% CI | Itchy rash during the last 12 months  (%) | 95% CI | Itchy rash during the last 12 months  (%) | 95% CI |  | Point prevalence  (%) | 95% CI | Point prevalence  (%) | 95% CI | Itchy rash during the last 12 months  (%) | 95% CI | Itchy rash during the last 12 months  (%) |
| Anandan C et al. 2009 (87) | 11.6 | 11.1 –12.1 | 8.8 | 8.4 – 9.2 |  |  |  |  |  |  |  |  |  |  |  |  |
| Chen GY et al. 2008 (226) | boys:girls ratio: 1.49:1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Christiansen et al. 2016 (230) |  |  |  |  |  |  |  |  |  |  |  |  | 7.0 |  | 5.0 |  |
| Civelek et al. 2011 (35) | 58.7% of all with AD# |  | 51.3% of all with AD# |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Hwang et al. 2010 (255) |  |  |  |  |  |  |  |  |  |  |  |  | 7.5 |  | 5.9 |  |
| Kay J et al. 1994 (265)  3-5y |  |  |  |  | 15% AD during the last year |  | 10% AD during the last year |  | 19.0 |  | 20.0 |  |  |  |  |  |
| Kay J et al. 1994 (265)  9-11y |  |  |  |  | 8% AD during the last year |  | 14% AD during the last year |  | 19.0 |  | 20.0 |  |  |  |  |  |
| Leung R et al. 1997 (278) |  |  |  |  | 4.7 | 3.8–5.5 | 4.3 | 3.4–5.1 | Eczema ever 17 | 15–18 | 14.0%Eczema ever | 12–15 | Itchy rash ever  5.6 | 4.7–6.5 | Itchy rash ever  5.2 | 4.3–6.1 |
| Liebhart J et al. 2014 (279) | 2.0 |  | 1.1 |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Yemaneberhan, H et al. (26) |  |  |  |  | 0.6 |  | 0.8 |  | 1.0 |  | 1.4 |  |  |  |  |  |

**Supplement 8:** Summary of study results prevalence by sex in adults

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Author, year, reference;  and age if applicable | female | | male | | female | | male | | female | | male | | female | | male | |
| Point prevalence  prevalence  (%, year if applicable&) | 95% CI | Point prevalence  (%) | 95% CI | Itchy rash during the last 12 months  (%) | 95% CI | Itchy rash during the last 12 months  (%) | 95% CI |  | Point prevalence  (%) | 95% CI | Point prevalence  (%) | 95% CI | Itchy rash during the last 12 months  (%) | 95% CI | Itchy rash during the last 12 months  (%) |
| Dalgård et al. 2004 (232) | 4.7 |  | 6.2 |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Kurt E et al. 2009 (354) |  |  |  |  | 13.1 | 12.4-13.8 | 10.8 | 10.2-11.4 |  |  |  |  |  |  |  |  |
| Mortz CG et al. 2001 (290) |  |  |  |  |  |  |  |  |  |  |  |  | Lifetime prevalence of AD  17.0 |  | Lifetime prevalence of AD  25.7 |  |
| Okada Y et al. 2016 (295) |  |  | 6.7 |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Smith-Sivertsen T et al. 2003 (309) | 12.0-19.0 |  | 10.4-13.8 |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Ziyab A H et al. 2017 (28) | 10.2 | nr | 5.8 | nr | 24.3 | nr | 17.2 | nr | 23.0 | nr | 10.8 | nr | 19.1 | nr | 13.1 | nr |

y years